Vaxcyte, Inc.
825 Industrial Road, Suite 300
San Carlos
CA
94070
United States
Tel: (650) 837-0111
Website: https://vaxcyte.com/
Email: info@Vaxcyte.com
About Vaxcyte, Inc.
Vaxcyte, Inc. (Nasdaq: PCVX) is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent some of the most common and deadly infectious diseases worldwide. Our exclusively licensed cell-free protein synthesis platform and our proprietary know how enable us to design and produce optimized protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies cannot. Our lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Our pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.
97 articles about Vaxcyte, Inc.
-
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
4/2/2024
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.
-
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
3/4/2024
Vaxcyte, Inc. today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants.
-
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/27/2024
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2/15/2024
Vaxcyte, Inc. announced that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024.
-
As Vaxcyte targets it’s the pneumococcal vaccine market, the company is facing significant competition from major pharma companies already in the space.
-
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/2/2024
Vaxcyte, Inc. announced the closing of its previously announced underwritten public offering of 12,695,312 shares of common stock at a public offering price of $64.00 per share and pre-funded warrants to purchase 781,250 shares of common stock at a public offering price of $63.999 per underlying share.
-
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
2/1/2024
Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.
-
Vaxcyte Announces Pricing of $750 Million Public Offering
1/31/2024
Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants - Jan 30, 2024
1/30/2024
Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
-
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
1/29/2024
Vaxcyte today announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.
-
Vaxcyte Appoints Whitney Jones as Chief People Officer
1/16/2024
Vaxcyte, Inc. today announced the appointment of Whitney Jones as Chief People Officer.
-
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
1/4/2024
Vaxcyte, Inc. announced an update regarding the ongoing progress of the Company’s pneumococcal conjugate vaccine franchise.
-
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
12/4/2023
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the publication of the results from the VAX-24 Phase 1/2 clinical proof-of-concept study in the journal The Lancet Infectious Diseases.
-
Vaxcyte Appoints Jacks Lee to Board of Directors
11/28/2023
Vaxcyte, Inc. today announced the appointment of Jacks Lee to its Board of Directors.
-
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
11/27/2023
Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) today announced that Vaxcyte has exercised its option and entered into a manufacturing rights agreement with Sutro to obtain control over the development and manufacture of cell-free extract, a key component of Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-24 and VAX-31.
-
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
11/9/2023
Vaxcyte, Inc. today announced that the first participants were dosed in a Phase 1/2 clinical study for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in adults.
-
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
11/6/2023
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.
-
Vaxcyte to Present at Upcoming November 2023 Investor Conferences
10/31/2023
Vaxcyte, Inc. announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences.
-
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
10/19/2023
Vaxcyte, Inc. (Nasdaq: PCVX) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).
-
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
10/16/2023
Vaxcyte, Inc. (Nasdaq: PCVX) and Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the companies have entered into a new commercial manufacturing agreement.